within Pharmacolibrary.Drugs.ATC.L;

model L04AA22
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AA22</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Abetimus is a synthetic double-stranded oligonucleotide that acts as an immunosuppressive agent by inhibiting the production of anti-double stranded DNA antibodies. It was developed for the treatment of systemic lupus erythematosus (SLE) but was never approved, and its development has been discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters based on pharmacological class and physicochemical properties, as no published clinical pharmacokinetic data are available for abetimus in humans.</p><h4>References</h4><ol><li><p>Linnik, MD, et al., &amp; Crowther, MA (2008). Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. <i>Journal of clinical pharmacology</i> 48(8) 909–918. DOI:<a href=\"https://doi.org/10.1177/0091270008319465\">10.1177/0091270008319465</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18511650/\">https://pubmed.ncbi.nlm.nih.gov/18511650</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AA22;
